Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

erapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mCRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of hormone refractory prostate cancer (HRPC). Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in humans. Fo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... shareholder letter from Mr. Yanqing Liu, the Company,s Chairman ... full text of this shareholder letter is as follows: ...
... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
Cached Medicine Technology:Shareholder Letter from Chairman of China Sky One Medical 2Shareholder Letter from Chairman of China Sky One Medical 3Shareholder Letter from Chairman of China Sky One Medical 4VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los ... in need. Most people know that general health emergencies, such as broken arms or ... of people know where to turn to during a dental emergency. This is important, ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Government Programs, with accountability for overall performance of the company’s Medicare and Federal ... focus of Cambia’s strategy to deliver better health for members. In this role, ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... chapping, experts advise , SATURDAY, Dec. 26 (HealthDay News) ... humidity, and the air inside is heated and dry, you ... say. , To prevent scaling, flaking and itching, pay special ... a cream-based moisturizer every day, recommends Dr. Anjali Dahiya, a ...
... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
... to those in pot that increase the response to sweets ... some light on the "munchies" -- the desire that pot ... the active ingredient in marijuana, is similar to substances known ... and enhance the perception of sweet foods, researchers say. , ...
... Mouse study holds promise for humans with hereditary disease ... reporting that they,ve discovered a molecular switch that appears ... in mice. , An estimated one out of every ... and disrupts a person,s ability to walk, talk, think ...
... , WASHINGTON, Dec. 24 This ... final passage of HR 3590, the so-called "Patient Protection and ... Research Council President Tony Perkins made the following comments: , ... debate in the Senate, but it,s far from the end ...
... Bill Must Be Improved: Anti-Choice Provisions in Senate and House ... Affordable , WASHINGTON, Dec. 24 The following ... for Women & Families: , "The Senate took a historic ... morning by passing comprehensive reform that will cover 31 million ...
Cached Medicine News:Health News:Skin Needs Protection From Winter Weather 2Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:FRC Statement on the Christmas Eve Passage of the Health Care 'Reform' Bill 2Health News:Senate Passage of Health Reform a Historic Milestone, National Partnership President Says 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: